October 11, 2016 (Shareholders Foundation) - An investigation on behalf of investors of KemPharm Inc (NASDAQ:KMPH) shares over potential securities laws violations by KemPharm Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of KemPharm Inc (NASDAQ:KMPH) concerning whether a series of statements by KemPharm Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

KemPharm Inc conducted its initial public offering in April 2015. Shares of KemPharm Inc (NASDAQ:KMPH) reached as high as $23.63 per share in September 2015.

On May 5, 2016, KemPharm Inc announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had reviewed and voted on Apadaz, determining by a vote of 16 to 4 that Apadaz should be approved for its proposed indication of the management of acute pain that requires an opioid, but voted 18 to 2 against inclusion of abuse deterrent labeling for the product.

Shares of KemPharm Inc (NASDAQ:KMPH) declined from $18.53 per share in late April 2016 to as low as $3.69 per share in July 2016.